QuantalX NeuroScience News
8 articles
growth-positive
/PRNewswire/ -- QuantalX Neuroscience Ltd. is proud to announce that its groundbreaking brain health assessment device, the Delphi-MD, has received CE MDR...
QuantalX Neuroscience Ltd. has announced that its Delphi-MD neurodiagnosis medical device has received CE MDR approval, paving the way for its commercialization across Europe. The device aims to improve brain health assessment and early detection of neurological disorders such as stroke, Parkinsons disease, and dementia. With the aging population in Europe, the demand for advanced neurological care solutions is increasing. The CE MDR certification highlights the safety, efficacy, and quality of Delphi-MD, underscoring QuantalXs commitment to innovation in neurological care. The device is expected to enhance patient outcomes and reduce the economic burden on healthcare systems.
Product Stage
growth-positive
QuantalX Secures FDA Clearance For Its Breakthrough Delphi Stimulator, Advancing Direct Brain Health Diagnosis At The Point Of Care
QuantalX Neuroscience Ltd. has announced that its Delphi-MD platform, a neurodiagnostic tool, has received FDA clearance for its Delphi stimulator. This milestone positions Delphi-MD as a new standard in brain health diagnostics, offering non-invasive, radiation-free insights into brain function. The platform aids in the early detection of various brain conditions, including stroke and dementia, and supports precision-tailored treatments. Delphi-MD has been granted FDA Breakthrough Designation Device status twice and has been selected for the FDA Total Product Life Cycle Advisory program. The company aims to revolutionize neurodiagnostics and enhance patient care as it expands its presence in the US healthcare market.
growth-positive
QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson's Disease
QuantalX Neuroscience has announced a significant breakthrough in the early diagnosis and subtyping of Parkinson’s disease, utilizing their innovative Delphi-MD device. This advancement, published in npj Parkinson’s Disease by Nature Magazine, is part of QuantalXs broader neurological disease diagnostic portfolio. The Delphi-MD device uses direct electrophysiological imaging technology to provide real-time insights into brain network function, allowing for early intervention and personalized treatment. This technology is set to transform clinical practice by improving treatment selection and disease monitoring, offering real-time insights for personalized therapeutic strategies and better patient care. The development is expected to benefit patients, healthcare systems, payors, and pharmaceutical companies, marking a new era in personalized neurological care.
growth-positive
QuantalX Partners with the University of Illinois Chicago, Towards Successful US Commercialization
QuantalX Neuroscience Ltd has announced a partnership with the Department of Neurology and Rehabilitation at the University of Illinois Chicago (UIC). This collaboration marks a significant step in QuantalXs efforts to commercialize its Delphi-MD technology in the US. The partnership involves two groundbreaking studies using Delphi-MD: one for predicting post-stroke neurological deterioration in acute ischemic stroke patients, and another for evaluating brain changes in Sickle Cell Disease patients. The collaboration aims to enhance patient care and outcomes through precise neuro-physiological assessments and predictive analytics. This partnership is expected to contribute significantly to QuantalXs mission of improving brain health care standards.
Partners
growth-positive
QuantalX Partners with Sheba Longevity Center to Advance Brain Health Across Lifespan
QuantalX Neuroscience, a leading medical device company specializing in brain health diagnosis, has announced a significant partnership with The Sheba Longevity Center, part of the Sheba Medical Center in Israel. This collaboration aims to advance brain health diagnostics and intervention strategies, focusing on proactive healthcare management and early detection of brain abnormalities. By leveraging QuantalXs Delphi-MD technology and Shebas expertise, the partnership seeks to enhance the quality of life for aging populations worldwide. The collaboration will focus on developing a risk prediction model for early detection of mild cognitive impairment, marking a transformative shift in healthcare. This partnership underscores QuantalXs commitment to innovative healthcare solutions and improving health outcomes globally.
Partners
growth-positive
QuantalX Secures Spot in FDA's Prestigious Total Life Cycle Advisory Program (TAP)
QuantalX Neuroscience has been selected by the FDA for the Total Life Cycle Advisory Program (TAP), marking a significant milestone as it enters the global commercialization phase. This program will advance the Delphi-MD medical device, which uses Direct Electrophysiology Imaging technology for early detection of Normal Pressure Hydrocephalus (NPH). The TAP program involves collaboration with major health insurers, healthcare organizations, and industry leaders to create a strategy for market entry and regulatory approval. This opportunity positions QuantalX for a stronger market presence and enhances its commitment to neurodiagnosis excellence. The Delphi-MD device aims to improve patient care by facilitating quick and accurate brain health assessments, reducing misdiagnosis rates, and enhancing patient well-being.
CustomersPartners
growth-positive
QuantalX Secures Dedicated Reimbursement Code for Delphi-MD Test, Advancing Improved Brain Health
QuantalX Neuroscience has achieved a significant milestone by securing a US reimbursement code, 0858T, from the American Medical Association for its Delphi-MD brain health test. This development is part of QuantalXs pre-commercialization strategy in the US, aiming to drive widespread adoption of its technology. The Delphi-MD test, which has received Breakthrough FDA Designation for two indications, offers an automated approach to brain health assessment, improving early detection and treatment outcomes. QuantalX has also established a new headquarters in New York City, reflecting its commitment to expanding its US presence and fostering relationships with potential clients and partners. The company is poised to make a significant impact on early brain disorder detection and enhance healthcare outcomes.
CustomersExpand
growth-positive
DELPhi- A New Groundbreaking Technology for Brain Health Imaging
An article discusses a new technology called DELPhi, developed by QuantalX NeuroScience, which is a non-invasive and direct tool for evaluating and monitoring brain health. The article highlights the importance of early detection and continuous monitoring of brain health to prevent brain diseases. DELPhi is able to detect subtle changes in brain health with aging and track abnormal brain function in early stages of Dementia. The technology works by pinging the brain with a magnetic pulse and analyzing the brains response. The article emphasizes the potential of DELPhi in overcoming aging brain diseases like Alzheimers and Dementia. The article does not mention any specific customers, partners, investment, acquisition, or layoffs. The date of the event described in the article is September 18, 2019.
Customers
